ArticleJournal of orthopaedic surgery and research2025
Burden of screening and treatment of bone health markers amongst elderly patients with proximal femur fractures.
Article in Journal of orthopaedic surgery and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThis study aims to quantify changes in the burden of screening for osteoporosis and vitamin D deficiency (VDD) amongst elderly patients treated with proximal femur fracture repair (PFFR).
methodsData collection and analysis was performed via the TriNetX HCO group network titled Research. Patients aged 65 and older who underwent PFFR were included based on CPT codes. Rates of preexisting diagnoses of VDD and/or osteoporosis, and first-time diagnoses of VDD or osteoporosis at 1 month, 6 months, and 1 year following PFFR between 2004 and 2024 were explored. Patient demographics and comorbidity data were compared across patient cohorts using chi-square tests for categorical variables, independent samples t-tests for continuous variables. Standardized differences were used to calculate the effect size.
resultsPFFRs registered in TriNetX have increased from 2004 to 2024 (Table 1). Those patients who underwent PFFR without prior history of VDD and/or osteoporosis ranged from 74.60% in 2004 to 49.83% in 2024. Conversely, patients with a prior history of documented VDD and/or osteoporosis ranged from 25.4% in 2004 to 50.1% in 2024. The percent risk of a first-time diagnosis of osteoporosis at 1 month, 6 months, and 1 year in the overall cohort were 3.7%, 8.6%, and 10.3%, respectively. The percent risk of a first-time diagnosis of VDD at 1 month, 6 months, and 1 year in the overall cohort were 2.1%, 4.4%, and 5.6%, respectively.
conclusionThe burden of screening for markers of bone health and subsequent treatment in at risk patients has increased over time. Rates of first-time diagnoses of osteoporosis or VDD after PFFR represent a current treatment burden of approximately 10% and 5% of this population at 1 year, respectively. This number may underrepresent the true burden of disease, highlighting the necessity of screening protocols targeting this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.